TITLE:
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

CONDITION:
Chronic Hepatitis B

INTERVENTION:
Entecavir

SUMMARY:

      The purpose of this clinical research study is to assess the safety and effectiveness of
      entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B
      infection who are hepatitis B e antigen negative.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 16 Years to N/A
Criteria:

        -  Male and female subjects =/> 16 years of age (or minimum age required in a given
             country) with history of chronic hepatitis B infection;

          -  HBeAg negative, anti-HBeAb positive;

          -  Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus
             (HCV) or hepatitis D virus (HDV);

          -  Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease;

          -  Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral
             agents with activity against hepatitis B (e.g., adefovir, famciclovir and lamivudine)
      
